-transparent.png){kind=logo}
In the series of tetraalkylammonium ions from tetramethylammonium to tetra-n-heptylammonium, tetra-n-pentylammonium ion was a potent protector of both murine L1210 leukemia and bone marrow progenitor cells against mechlorethamine cytotoxicity. It was also a non-competitive inhibitor of choline uptake. Phosphonium analogs of the tetraalkylammonium ions were equal to their corresponding tetraalkylammonium ions in their protection against mechlorethamine cytotoxicity and in their inhibition of choline uptake. Treatment of tumor bearing L1210 leukemia mice with the combination of tetra-n-pentylammonium ion and mechlorethamine resulted in no major improvement in survival of the tumor-bearing mice compared to mechlorethamine treatment alone.
S A Naujokaitis, and
J M Fisher, and
M Rabinovitz
May 1981,
Research communications in chemical pathology and pharmacology,
S A Naujokaitis, and
J M Fisher, and
M Rabinovitz
October 1981,
Research communications in chemical pathology and pharmacology,
S A Naujokaitis, and
J M Fisher, and
M Rabinovitz
June 1981,
Research communications in chemical pathology and pharmacology,
S A Naujokaitis, and
J M Fisher, and
M Rabinovitz
January 1983,
Cancer chemotherapy and pharmacology,
S A Naujokaitis, and
J M Fisher, and
M Rabinovitz
September 1980,
Blood,
S A Naujokaitis, and
J M Fisher, and
M Rabinovitz
January 1978,
Biochemical pharmacology,
S A Naujokaitis, and
J M Fisher, and
M Rabinovitz
January 1979,
Research communications in chemical pathology and pharmacology,
S A Naujokaitis, and
J M Fisher, and
M Rabinovitz
November 1991,
Toxicology letters,
S A Naujokaitis, and
J M Fisher, and
M Rabinovitz
November 1978,
Molecular pharmacology,
S A Naujokaitis, and
J M Fisher, and
M Rabinovitz
March 1984,
Cancer treatment reports,
